Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$94.31 USD

94.31
41,702

-0.96 (-1.01%)

Updated May 21, 2024 10:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 248)

Industry: Medical - Products

Better trading starts here.

Zacks News

Quest Diagnostics (DGX) to Boost Lab Services With New Buyout

Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.

Here's Why You Should Retain Omnicell (OMCL) Stock Now

Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on strong solvency and promising future strategies.

Tandem Diabetes (TNDM) and Abbott Debut New Integrated Offering

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system to be integrated with Abbott's Freestyle Libre 2 Plus sensor.

Chemed (CHE) Roto-Rooter Growth Continues, Macro Issues Hurt

Within the Hospice segment, Chemed (CHE) is well poised to register growth driven by the growing aging population.

Asensus Surgical (ASXC) Completes Surgeon Lab for LUNA

Asensus Surgical's (ASXC) latest Surgeon Lab helps it move closer to a finalized LUNA product.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy Amid Industry Challenges

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. PHG, NEOG, HAE and PBH are well-poised to gain from the favorable factors.

Boston Scientific (BSX) Rides on Global Growth Amid Macro Woes

Within APAC, Boston Scientific (BSX) is registering strong growth in Japan and China.

Bruker's (BRKR) New Deal Widens Biopharma PAT Product Portfolio

Bruker (BRKR) announces the acquisition of Tornado Spectral Systems Inc., a global provider of chemical analysis & measurement systems for Raman spectroscopy.

Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Bruker (BRKR) Expands Materials Science Research via New Deal

Bruker (BRKR) announces the acquisition of the electron microscopy company Nion.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

Investors continue to remain optimistic about STERIS (STE) due to the prospects of the healthcare business.

Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.

HAE or SYK: Which Is the Better Value Stock Right Now?

HAE vs. SYK: Which Stock Is the Better Value Option?

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial

Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.

Here's Why Haemonetics (HAE) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.